1. Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b–2 study. Issue 7 (July 2019) Authors: Tilly, Hervé; Morschhauser, Franck; Bartlett, Nancy L; Mehta, Amitkumar; Salles, Gilles; Haioun, Corinne; Munoz, Javier; Chen, Andy I; Kolibaba, Kathryn; Lu, Dan; Yan, Mark; Penuel, Elicia; Hirata, Jamie; Lee, Calvin; Sharman, Jeff P Journal: Lancet oncology Issue: Volume 20:Issue 7(2019) Page Start: 998 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Phase 1b, open-label study evaluating the safety and pharmacokinetics of atezolizumab (anti–PD-L1 antibody) administered in combination with Hu5F9-G4 to patients with relapsed and/or refractory acute myeloid leukemia. Issue 11 (19th September 2022) Authors: Daver, Naval; Jonas, Brian A.; Medeiros, Bruno C.; Patil, Upen; Yan, Mark Journal: Leukemia & lymphoma Issue: Volume 63:Issue 11(2022) Page Start: 2711 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. A phase 1b study of atezolizumab in combination with guadecitabine for the treatment of acute myeloid leukemia. Issue 9 (29th July 2022) Authors: Prebet, Thomas; Goldberg, Aaron D.; Jurcic, Joseph G.; Khaled, Samer; Dail, Monique; Feng, Yuning; Green, Cherie; Li, Chunze; Ma, Connie; Medeiros, Bruno C.; Yan, Mark; Grunwald, Michael R. Journal: Leukemia & lymphoma Issue: Volume 63:Issue 9(2022) Page Start: 2180 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗